RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Shandong Cancer Hospital and Institute; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Shandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07340515, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed nasopharyngeal carcinoma (WHO type II or III)

    Inclusion criterion 2

  3. High-risk locoregionally advanced disease defined as clinical stage T4 or N3, M0, according to the AJCC staging system

    Inclusion criterion 3

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

    Inclusion criterion 5

  5. Pregnancy or breastfeeding

    Exclusion criterion 5

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07340515, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18 to 70 years
  • Histologically confirmed nasopharyngeal carcinoma (WHO type II or III)
  • High-risk locoregionally advanced disease defined as clinical stage T4 or N3, M0, according to the AJCC staging system
  • No prior anti-tumor therapy for nasopharyngeal carcinoma, including radiotherapy, chemotherapy, targeted therapy, or immunotherapy
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Adequate organ function as defined in the study protocol
  • Eligible to receive induction chemotherapy followed by concurrent chemoradiotherapy combined with immunotherapy as specified in the protocol
  • Ability to understand and willingness to sign written informed consent

Exclusion Criteria:

  • Evidence of distant metastasis (M1 disease)
  • Prior radiotherapy, chemotherapy, targeted therapy, or immunotherapy for nasopharyngeal carcinoma
  • Active autoimmune disease requiring systemic therapy
  • Uncontrolled infection or severe comorbidities that may affect treatment tolerance
  • Pregnancy or breastfeeding
  • Known allergy, hypersensitivity, or contraindication to study medications as defined in the protocol
  • Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation

Quoted from ClinicalTrials.gov, NCT07340515, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07340515, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07340515